September 23, 2015

Helix BioPharma Corp. Announces Director Resignation (PDF)

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Stacy L. Wills has voluntarily resigned from Helix’s board of directors, effective as of September 25, 2015.